Skip to Content

Fisher & Paykel Healthcare Corp Ltd

FPH: XASX (AUS)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
A$92.00XbhjhGxgxhqgh

Fisher & Paykel Earnings: Strong Demand in Homecare Consumables and Resilient Margins

We raise our fair value estimate for narrow-moat Fisher & Paykel by 2% to NZD 22.50, or AUD 21.00 at current exchange rates, largely due to the time value of money. First-half revenue grew 16% to NZD 804 million and net profit after tax grew 22% to NZD 107 million, both slightly ahead of prior guidance. Management reiterated its fiscal 2024 revenue guidance of roughly NZD 1.7 billion but also provided fiscal 2024 NPAT guidance of NZD 250 million-NZD 260 million. The guidance implies a stronger second half reflective of typical seasonality given the North American flu season.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of FPH so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center